Medical education company Amboss secures $260M for global expansion
Amboss, a medical education company for medical students and healthcare stakeholders, closed a €240 million ($259.44 million) financing round.
The round included new primary investors KIRKBI, M&G Investments and Lightrock with participation from existing shareholders. The company recently converted to a European stock corporation (SE).
WHAT IT DOES
Amboss helps medical students and professionals access information. Its platform includes a program designed to help students study for the U.S. medical licensing exams and national board exams.
The company will use the funds to add international markets and expand its offering to nurses and other healthcare professionals.
“We choose investors who are committed to our long-term vision and very flexible in the investment duration,” Benedikt Hochkirchen, cofounder and co-CEO of Amboss, said in a statement.
“Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond. Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”
MARKET SNAPSHOT
In 2024, Amboss acquired Novaheal, an EdTech startup that offers a platform for nursing education. The acquisition expanded Amboss’ offerings for physicians and nurses to include tools pertaining to education, training and daily practice.
That same year, Amboss acquired NEJM Knowledge plus, a learning and assessment tool for clinicians created by NEJM Group, publishers of the New England Journal of Medicine.
Integrating NEJM Knowledge plus with Amboss’s clinical support tool offered a resource for healthcare professionals who want easily accessible and actionable medical information as a way of building their knowledge base and driving clinical decision-making.
Saint James School of Medicine in Anguilla partnered with Amboss. The Amboss platform integrates with the curriculum pertaining to the first sixteen months of SJSM’s basic sciences program.
In 2019, Amboss secured €30 million ($32.7 million) in Series B funding. The round was led by Partech’s growth fund, with participation from Cherry Ventures, Wellington Partners and Holtzbrinck Digital.
